Phyllodes tumours of the breast: a consensus review by Tan, Benjamin Y. et al.
Phyllodes tumours of the breast: a consensus review
Benjamin Y Tan, Geza Acs1, Sophia K Apple2, Sunil Badve3, Ira J Bleiweiss4, Edi Brogi5, 
José P Calvo6, David J Dabbs7, Ian O Ellis8, Vincenzo Eusebi9, Gelareh Farshid10, Stephen 
B Fox11, Shu Ichihara12, Sunil R Lakhani13, Emad A Rakha8, Jorge S Reis-Filho5, Andrea L 
Richardson14, Aysegul Sahin15, Fernando C Schmitt16, Stuart J Schnitt17, Kalliopi P 
Siziopikou18, Fernando A Soares19, Gary M Tse20, Anne Vincent-Salomon21, and Puay 
Hoon Tan
Department of Pathology, Singapore General Hospital, Singapore
1Women’s Pathology Consultants, Ruffolo Hooper & Associates, Tampa, FL, USA
2Department of Pathology, UCLA Medical Center, Santa Monica, CA, USA
3Departments of Pathology and Internal Medicine, Clarian Pathology Laboratory of Indiana 
University, Indianapolis, IN, USA
4Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
5Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
6Servicio de Anatomía Patológica, Hospital Universitario Ramón y Cajal, Madrid, Spain
7University of Pittsburgh Medical Center, Pittsburgh, PA, USA
8Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, 
Nottingham, UK
9Sezione Anatomia e Istologia Patologica, ‘M. Malpighi’ Università di Bologna, Bologna, Italy
10BreastScreen SA, Discipline of Medicine, Adelaide University and Directorate of Surgical 
Pathology, SA Pathology, Adelaide, South Australia
11Pathology Department, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, 
Vic., Australia
12Department of Pathology, Nagoya Medical Center, Nagoya, Japan
13School of Medicine and Pathology Queensland, The Royal Brisbane & Women’s Hospital, 
University of Queensland Centre for Clinical Research, Brisbane, Qld, Australia
14Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, 
MA, USA
15Department of Pathology, Division of Pathology/Laboratory Medicine, University of Texas MD 
Anderson Cancer Center, Houston, TX, USA
Address for correspondence: Dr Puay Hoon Tan, Department of Pathology, Singapore General Hospital, Diagnostics Tower, Level 7, 
Academia, 20 College Road 169856, Singapore. tan.puay.hoon@sgh.com.sg. 
Conflicts of interest
The authors declare no conflicts of interest with respect to the authorship, research and/or publication of this article
HHS Public Access
Author manuscript
Histopathology. Author manuscript; available in PMC 2016 September 19.
Published in final edited form as:
Histopathology. 2016 January ; 68(1): 5–21. doi:10.1111/his.12876.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Tan, B. Y., Acs, G., Apple, S. K., Badve, S., Bleiweiss, I. J., Brogi, E., ... & Farshid, G. (2016). Phyllodes tumours of the breast: a 
consensus review. Histopathology, 68(1), 5-21. https://doi.org/10.1111/his.12876
16Laboratoire national de santé, Luxembourg city, Luxembourg
17Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
18Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer 
Center, Chicago, IL, USA
19Department of Anatomic Pathology, A. C. Camargo Cancer Centre, São Paulo, Brazil
20Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese 
University of Hong Kong, Shatin, Hong Kong
21Pôle Pathologie-Génétique-Immunologie, Institut Curie, Paris, France
Abstract
Phyllodes tumours constitute an uncommon but complex group of mammary fibroepithelial 
lesions. Accurate and reproducible grading of these tumours has long been challenging, owing to 
the need to assess multiple stratified histological parameters, which may be weighted differently 
by individual pathologists. Distinction of benign phyllodes tumours from cellular fibroadenomas is 
fraught with difficulty, due to overlapping microscopic features. Similarly, separation of the 
malignant phyllodes tumour from spindle cell metaplastic carcinoma and primary breast sarcoma 
can be problematic. Phyllodes tumours are treated by surgical excision. However, there is no 
consensus on the definition of an appropriate surgical margin to ensure completeness of excision 
and reduction of recurrence risk. Interpretive subjectivity, overlapping histological diagnostic 
criteria, suboptimal correlation between histological classification and clinical behaviour and the 
lack of robust molecular predictors of outcome make further investigation of the pathogenesis of 
these fascinating tumours a matter of active research. This review consolidates the current 
understanding of their pathobiology and clinical behaviour, and includes proposals for a rational 
approach to the classification and management of phyllodes tumours.
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Introduction
Phyllodes tumours of the breast constitute an uncommon but fascinating group of 
fibroepithelial neoplasms that have a morphological resemblance to the intracanalicular 
fibroadenoma at the benign end of the spectrum, but with increased stromal cellularity and 
leaf-like architecture. Phyllodes tumours are classified into benign, borderline and malignant 
grade categories on the basis of a constellation of histological parameters, i.e. the degree of 
stromal cellularity and atypia, mitotic count, stromal overgrowth, and the nature of their 
tumour borders.1 As each microscopic parameter has two to three tiers of stratification, there 
are significant challenges in accurate and reproducible categorization.
Apart from grading difficulties, the benign phyllodes tumour shows overlapping features 
with cellular fibroadenoma, whereas, at the other end of the spectrum, the malignant 
phyllodes tumour may be mistaken for primary breast sarcoma or spindle cell metaplastic 
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carcinoma. The distinction between benign phyllodes tumour and cellular fibroadenoma is 
especially problematic on core biopsies. Currently, cellular fibroepithelial lesions diagnosed 
on core biopsy may be subjected to complete removal through either vacuum-assisted or 
open excision. Surgical excision is usually the preferred procedure, as it allows negative 
margins to be obtained in the event that the final diagnosis is a phyllodes tumour. What 
constitutes a sufficient margin for phyllodes tumours is yet another unresolved dilemma.
Debate regarding the relationship between fibroadenoma, a common benign neoplasm, and 
phyllodes tumour, a rare tumour with uncertain behaviour, continues. Fibroadenoma-like 
areas are not infrequently encountered in phyllodes tumours, although the frequency of such 
an observation is not known.
In this review, we provide a collective stance on these issues that can serve as a practical 
guide for pathological reporting and understanding of phyllodes tumours.
Grading of phyllodes tumours
The criteria for diagnosis and grading of phyllodes tumours are summarized in the 
recommendations of the World Health Organization (WHO) classification of tumours of the 
breast.1 Briefly, phyllodes tumours are diagnosed when the fibroepithelial architecture 
shows an exaggerated intracanalicular pattern with leaf-like fronds protruding into cystically 
dilated spaces accompanied by stromal hypercellularity. A benign phyllodes tumour shows 
mildly increased stromal cellularity as compared with a fibroadenoma, and has minimal 
nuclear atypia, pushing borders, and mitoses of ≤4/10 high-power fields (HPFs). Stromal 
overgrowth (defined as the presence of stroma without epithelium in at least one low-power 
field as observed with a × 4 microscope objective) is not present. The key feature 
distinguishing a benign phyllodes tumour from a fibroadenoma with an exaggerated 
intracanalicular growth pattern is the presence of increased stromal cellularity. In the 
absence of well-developed stromal fronds, the presence of elongated, branching and cleft-
like ducts meandering through the cellular stroma, giving a staghorn appearance, may be a 
histological clue to the diagnosis of a phyllodes tumour.
At the other end of the spectrum, a malignant phyllodes tumour shows marked stromal 
cellularity and atypia, has permeative margins, and has mitotic activity of at least 10/10 
HPFs. Stromal overgrowth is usually easily identified. Phyllodes tumours with intermediate 
features are assigned to the borderline category. Previous grading schemes have assessed 
similar histological parameters, including that described by Azzopardi in 1979, which 
incorporated the nature of the tumour edge, stromal overgrowth, mitotic activity, and cellular 
atypia.2
It is important to acknowledge that there are no objective criteria for separating minimal/
mild from moderate and marked degrees of stromal hypercellularity and atypia, and this may 
confound grading attempts. A practical guide for assessing stromal cellularity is to centre on 
the most cellular zones of the lesion, with mild hypercellularity characterized by a slight 
increase in stromal cells as compared with normal perilobular stroma, with evenly spaced 
nuclei that are not touching or overlapping. Marked stromal cellularity shows confluent 
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areas of densely overlapping nuclei, whereas moderate stromal cellularity has findings that 
are intermediate, with some overlapping stromal nuclei (Figure 1). Mild stromal atypia 
shows nuclei with little variation in size, with smooth nuclear contours. Moderate atypia 
shows some variation in nuclear size, with wrinkled nuclear membranes, to an extent 
exceeding that in mild atypia but less than that in marked atypia. Marked atypia shows 
marked variation in nuclear size, coarse chromatin, and irregular nuclear membranes with 
discernible nucleoli (Figure 2).3
The perceived clinical relevance of grading phyllodes tumours is to predict clinical 
behaviour: benign tumours have the potential to locally recur; borderline tumours have the 
potential to recur locally, and have a very low risk of metastasis; and malignant tumours 
have the highest risk of metastatic behaviour, which may eventually prove fatal. However, it 
is accepted that adverse events are, in general, rare for all forms of phyllodes tumours when 
they are subjected to complete local excision.
Although the guidelines may appear straightforward, their application can be fraught with 
ambiguity. Furthermore, how the subdivisions for each microscopic parameter interact to 
constitute the final grade is subjective. It is also not uncommon for phyllodes tumours to 
show intratumoral heterogeneity, and harbour features that typify benign lesions in some 
areas, and characteristics of borderline and malignant lesions in other foci. For instance, a 
phyllodes tumour with marked stromal atypia and brisk mitotic activity, but without 
permeative margins or stromal overgrowth, may be considered by some pathologists to be 
borderline, whereas others may regard the tumour as malignant, owing to different 
weighting of the relevance of each feature, with prioritization of stromal atypia (Figure 3). A 
practical approach is to grade a phyllodes tumour as malignant when it shows all of the 
histological changes of malignancy, and as borderline when not all malignant characteristics 
are present. The presence of a malignant heterologous element such as liposarcoma, 
chondrosarcoma or osteosarcoma relegates the tumour into the malignant category 
regardless of whether other histological parameters (stromal hypercellularity, atypia, mitotic 
rate, overgrowth, and nature of tumour borders) show changes characteristic of malignant 
phyllodes tumours. In an effort to comprehend which microscopic parameters are more 
influential in determining the clinical behaviour of phyllodes tumours, a study of 605 cases 
concluded that stromal atypia, mitoses, overgrowth and surgical margins (AMOS criteria)4 
were of independent significance in predicting behaviour, with surgical margin status being 
the most important. A nomogram was developed by the use of a mathematical formula that 
could be applied to counsel patients about their individual risk for recurrence.4
Despite the host of biological markers studied in phyllodes tumours, many with an 
association with grade,5–13 their use in defining grade and potential clinical behaviour in 
specific cases remains limited.
Biological behaviour and metastatic potential of phyllodes tumours
Recurrence rates in a large Asian series of phyllodes tumours were 10.9%, 14.4% and 29.6% 
for benign, borderline and malignant phyllodes tumours, respectively. 4 In another review of 
33 cases from Germany, recurrence rates were reported to be 8%, 20% and 50% for benign, 
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borderline and malignant tumours, respectively,1 with distant metastases being encountered 
in 9% of patients with malignant tumours. Overall, recurrence rates in the literature are 10–
17%, 14–25% and 23–30% for benign, borderline and malignant phyllodes tumours, 
respectively.1 Interestingly, in a clinicopathological analysis by Karim et al., there was a 
suggestion that Asian patients experienced a higher recurrence rate than those of non-Asian 
ethnicity.14
Grade progression during local recurrence of phyllodes tumours can occur. There have been 
several suggestions regarding why this happens, including a lack of representative sampling 
of the initial tumour, tumour heterogeneity with the presence of stromal subclones,15 and 
loss of stromal–epithelial interdependency. 16
In a study of 335 phyllodes tumours, it was noted that metastases and death from phyllodes 
tumours were consistently preceded by a primary malignant diagnosis,17 suggesting that a 
key aim should be to recognize the malignant category, in order for effective therapy to be 
given at the outset. Metastases in phyllodes tumours invariably indicate a dismal prognosis, 
with ensuing death.4,18 Distant metastases occur mostly to the lung and skeleton, but almost 
all organ sites have been affected (Figure 4). Histologically, metastases comprise malignant 
stromal elements without accompanying epithelium.17,19,20 Two exceptional cases of 
metastatic phyllodes tumours harbouring an epithelial component have been described as 
case reports. One represented inclusion of lung alveolar tissue within the metastatic tumour 
stroma, as confirmed by immunoreactivity of the epithelial component for antisurfactant 
apoproteins.21 The other case showed floridly hyperplastic, adenosis-like epithelium, 
rimmed by actin and calponin-positive myoepithelial cells, within both the primary and 
metastatic tumours, which showed liposarcomatous differentiation.22 The metastatic 
epithelial component duplicated the immunoreactivity for oestrogen receptor (ER), 
progesterone receptor and gross cystic disease fluid protein 15 seen in the epithelium of the 
primary tumour.
How often do phyllodes tumours metastasize, and do benign tumours ever do so? Table 1 
shows metastatic rates according to phyllodes tumour grades that have been described by 
various authors.4,23–35 The singular documentations of metastatic disease following a 
diagnosis of benign phyllodes tumour were by Abdalla et al. and Chaney et al., where distant 
metastases were reported to occur in 3.2%, 11.1% and 28.6% of benign (1/31), borderline 
(3/27) and malignant (6/21) tumours,26 and in 1.7%, 0% and 26.7% of benign (1/59), 
borderline (0/12) and malignant (8/30) tumours,23 respectively. However, pathological 
details of these unusual cases of metastatic benign phyllodes tumour were not provided.
It may be reasonably inferred that metastatic disease is a vanishingly rare occurrence in 
benign phyllodes tumours, with the qualification that all tumours should be adequately 
sampled to account for intratumoral heterogeneity. Conversely, metastatic behaviour is an 
established risk for malignant phyllodes tumours, albeit still uncommon, and pathological 
diagnosis should focus on accurately identifying this group of tumours.
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Relationship between fibroadenoma and phyllodes tumour
Phyllodes tumours are generally regarded as de-novo lesions derived from periductal and 
specialized lobular stroma. The initiation of tumorigenesis may hinge on epithelial–stromal 
interactions. However, the histological overlap between fibroadenoma and phyllodes tumour 
has long raised the question of pathogenetic kinship. Table 2 shows the studies that have 
explored this relationship and their salient findings.36–50
Interestingly, a mother and daughter pair with benign phyllodes tumours was also described, 
raising the possibility of hereditary linkage,43 and a TP53 founder mutation was discovered 
in phyllodes tumours from Brazil.51 A study from France discovered chromosome 
imbalances in 55%, 91% and 100% of benign, borderline and malignant phyllodes tumours, 
respectively, with 1q gains being associated with borderline and malignant grades. It was 
suggested that phyllodes tumours could be divided into two genetically distinct classes, with 
benign tumours in one group and borderline/malignant phyllodes in the other.52
More recently, highly recurrent mediator complex subunit 12 (MED12) somatic mutations in 
exon 2 were discovered in 59% of 98 fibroadenomas studied, 44 with most mutations 
occurring in codon 44. The same mutation in MED12 is a common genetic anomaly in 
uterine smooth muscle tumours.53,54 Laser capture microdissection established that MED12 
mutations were present in stromal but not in epithelial cells of fibroadenomas. A subsequent 
study by Ng et al. found that MED12 mutations were also prevalent in phyllodes tumours, 
with 65.1% of benign, 65.6% of borderline and 42.8% of malignant phyllodes tumours, 
respectively, showing mutations. 50 The overall rate of MED12 mutations was strikingly 
similar in phyllodes tumours (62.5%) and fibroadenomas (59%), with a comparable rate of 
mutations in codon 44 of MED12 supporting a close molecular relationship.44,50 Other 
studies have confirmed the high prevalence of MED12 mutations in fibroadenomas and 
phyllodes tumours.45–49 Using targeted next-generation sequencing, Cani et al. found that 
malignant phyllodes tumours harboured additional genetic aberrations in tumour suppressor 
genes, consistent with their aggressive biological behaviour.45 Of particular prognostic 
import is the finding by Ng et al. that tumours with MED12 mutations were significantly 
associated with longer disease-free survival, possibly related to hormonal dependence.50
Although evidence for the direct evolution of phyllodes tumours from fibroadenomas 
remains limited, with very recent confirmation of linear progression in some cases,55 it is 
clear that these fibroepithelial lesions possess molecular similarities, in addition to their 
striking morphological resemblance in some cases.
Distinguishing cellular fibroadenoma from benign phyllodes tumour
In a study of 21 cellular fibroepithelial lesions evaluated by 10 specialist breast pathologists 
using the WHO criteria, only for two cases was uniform agreement achieved with regard to 
whether the lesion represented a cellular fibroadenoma or phyllodes tumour. It is noted, 
however, that these cases were highly selected from a consultation series, and problematic 
lesions were therefore over-represented.56 When cellular fibroadenomas and benign 
phyllodes tumours were combined and compared with borderline and malignant phyllodes 
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tumours as another group, the level of agreement improved considerably, with complete 
concordance in 53% of cases. These findings testify to the challenges of separating cellular 
fibroadenomas from benign phyllodes at one end of the spectrum, and also highlight the 
difficulty of achieving consensus in grading phyllodes tumours (Figure 5). It is important to 
note that fibroadenomas in the paediatric age group tend to have increased stromal 
cellularity, which should not be overinterpreted. 57 Of 68 paediatric breast fibroepithelial 
lesions analysed in a recent study, 16 cases showed mitotic activity. These included 15 
fibroadenomas of simple, cellular and juvenile types, 11 of which showed 1–2 mitoses/10 
HPF, and the remaining five fibroepithelial lesions showed mitotic activity ranging from 3 to 
5/10 HPF.57 In another study, by Ross et al., of breast fibroepithelial tumours in adolescent 
females aged up to 18 years, the mean stromal mitotic counts/10 HPF for 11 benign 
phyllodes tumours, five ‘usual’ fibroadenomas, 12 juvenile fibroadenomas and three 
‘variant’ juvenile fibroadenomas (with pericanalicular stromal expansion) were 3 (range: 1–
7), 1 (range: 0–2), 2 (range: 0–4) and 3 (range: 0–7), respectively.58 Faiz et al. also found 
stromal mitoses in all fibroadenoma subtypes (cellular, classic, and juvenile) among 119 
paediatric cases with up to 5 mitoses/10 HPF being observed in two cases.59 Therefore, 
apart from potentially increased stromal cellularity in paediatric fibroepithelial tumours, 
mitotic activity may also be encountered, up to 7 mitoses/10 HPF.57–59 A cautious and 
measured approach is therefore needed when cellular and mitotically active paediatric 
fibroepithelial lesions are evaluated. A diagnosis of phyllodes tumour should be based on the 
finding of well-developed stromal fronds accompanied by increased stromal hypercellularity.
Numerous studies have attempted to analyse the histology of phyllodes tumours.60–64 A 
study by Choi et al. found a concordance rate of only 60% between core needle biopsies and 
excision specimens, with larger tumour size being significantly correlated with discordant 
biopsy results.65 Assessment of clinicoradiological tumour attributes such as size and 
radiographic density may contribute to clinical decision-making. 66,67 Notwithstanding that, 
histomorphological assessment of the excised lesion remains the practical gold standard in 
diagnosis and grading,60,68 with the presence of leafy architecture and increased stromal 
cellularity typically being used as the discriminants between cellular fibroadenoma and 
benign phyllodes tumour. Fibroadenomas that contain stromal multinucleated giant cells can 
also be mistaken for phyllodes tumours,69 and there may be a potential role for Ki67 
proliferation activity as an adjunctive aid.3
The question of whether there is always a need to precisely delineate a benign phyllodes 
tumour from a cellular fibroadenoma arises. The answer is important, as many surgeons 
would perform a second surgical procedure to achieve negative margins for a benign 
phyllodes tumour initially enucleated without margin clearance. The WHO Working Group 
has proposed that the term ‘benign fibroepithelial neoplasm’ be employed in equivocal 
cases,70 in order to avoid overtreatment. This term, however, should be used sparingly, as it 
does not represent a new diagnostic category.
There has been both direct and indirect evidence that benign phyllodes tumours may be 
treated less aggressively. In a study of 37 women with locally recurrent phyllodes tumours, it 
was concluded that an expectant approach may be acceptable for initially diagnosed benign 
and borderline tumours, with complete resection being achieved during any subsequent 
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recurrent episode.27 Although most surgeons would be uncomfortable with not re-excising a 
borderline phyllodes tumour with positive margins, it would be reasonable to assume a 
‘watchful waiting’ strategy for benign lesions. The rate of recurrence for fibroadenomas 
after ultrasound-guided vacuum assisted percutaneous excision is listed as 15%,71 whereas 
Organ et al. described a recurrence rate of 17% for surgically excised fibroadenomas.72 
However, as acknowledged by the authors, determining whether the recurrence was a ‘true 
recurrence’ of the same tumour or another primary tumour was difficult, if not impossible, 
owing to the retrospective nature of the study, particularly if the same breast was involved. In 
a previous article, also by Organ,73 it was stated that ‘recurrences’ of fibroadenomas were 
undoubtedly serial presentations of multicentric lesions. This contrasts with a 10.9% 
recurrence rate of benign phyllodes tumours in one series,4 occurring typically at the site of 
previous surgery. A very low recurrence rate of 3.4% was reported in benign phyllodes 
tumours in a study by Korean investigators, with all recurrent cases remaining benign,74 
without any association with surgical margin status. Teo et al., in a retrospective review of 
44 Asian cases, found no cases of local recurrence in benign tumours treated with simple 
excision (enucleation), regardless of margin status, after a mean follow-up of 47.6 months.75 
Hence, a benign phyllodes tumour diagnosed after representative sampling of an excision 
specimen may be conservatively handled even when positive margins are encountered.
Conversely, malignant phyllodes tumours are associated with a recurrence rate of 29.6%4, 
with metastases and death being observed in 22%,1 underscoring the need to recognize this 
subset of aggressive phyllodes tumours for complete surgical eradication.
Distinguishing malignant phyllodes tumour from primary breast sarcoma 
and spindle cell metaplastic breast carcinoma
At the other end of the histological spectrum, a high-grade spindle cell neoplasm of the 
breast invokes different diagnostic considerations, namely malignant phyllodes tumour with 
sarcomatous overgrowth, spindle cell metaplastic breast carcinoma, and primary or 
secondary breast sarcoma.
The architectural hallmark of leaf-like fronds surmounted by benign glandular epithelium 
serves to delineate phyllodes tumour from its mimics. In some malignant phyllodes tumours, 
however, the stromal overgrowth may be so prominent that epithelial elements can be 
difficult to find, requiring extensive sampling with many sections for their identification. The 
stroma of a malignant phyllodes tumour may, on occasion, show heterologous sarcomatous 
differentiation, most frequently liposarcoma, but also including myosarcoma, angiosarcoma, 
chondrosarcoma, and osteosarcoma (Figure 6). A spindle cell metaplastic breast carcinoma 
contains varying proportions of a malignant epithelial component, which may be of 
squamous, glandular or adenosquamous type. Metaplastic carcinomas can also be entirely 
devoid of frank epithelial elements, or additionally show heterologous mesenchymal 
differentiation, although liposarcomatous elements are hardly ever seen. The presence of 
ductal carcinoma in situ adjacent to a malignant mammary spindle cell tumour greatly 
favours a diagnosis of metaplastic carcinoma. Primary breast sarcomas, which are distinctly 
uncommon,76 and sarcomas metastatic to the breast, which are exceptionally rare, have no 
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distinguishing histological features of either phyllodes tumour or metaplastic breast 
carcinoma, and can have histological attributes common to sarcomas at any site. A history of 
previous or metastatic sarcoma, imaging and clinical correlation may be helpful. Table 3 
summarises the features of these three entities.
On limited samples such as needle core biopsies, accurate diagnosis of high-grade malignant 
mammary spindle cell lesions can prove exceedingly challenging, especially when an 
epithelial element is elusive. The demonstration of diffuse cytokeratin or p63 
immunoreactivity in the malignant spindle cells supports a diagnosis of metaplastic 
carcinoma,77,78 although interpretation must be tempered in cases of focal keratin or p63 
expression, as such reactivities have been described in stromal cells of phyllodes 
tumours.79,80 The utility of p40 in a similar diagnostic setting remains under investigation; 
so far, it has been found to be more specific but less sensitive than p63.80–82 However, like 
p63, p40 may stain stromal cells of phyllodes tumours in some cases. CD34 reactivity, 
which is well described in the stromal cells of phyllodes tumours, has been reported to be 
inversely related to adverse histological features;6,8,13,83–86 this assumes importance if 
CD34 were to be considered for diagnostic utility in differentiating high-grade spindle cell 
lesions of the breast, as malignant phyllodes tumours are less likely to express CD34. Other 
markers, including bcl-286,87 which is more frequently expressed in phyllodes tumours, 
CD117,83,88,89 which shows increased expression in higher-grade phyllodes tumours, and 
sarcoma-specific molecular cytogenetic alterations are possible diagnostic adjuncts. 
Although routinely employed in the diagnosis of fibromatosis that may occur in the breast, 
aberrant nuclear expression of β-catenin has been reported in the stroma of phyllodes 
tumours, as well as in metaplastic carcinomas.90–94 The use of β-catenin as a solitary marker 
in the assessment of mammary spindle cell lesions must be cautioned against.
Adequate sampling, entailing at least one section per centimetre of maximal tumour size, 
with additional sampling of grossly heterogeneous areas and meticulous morphological 
assessment, remains the keystone of diagnosis, buttressed by clinical, radiological and 
immunohistochemical correlation.
Epithelial–stromal interactions in phyllodes tumours
In 1992, Sawhney et al. observed that stromal mitotic activity tended to occur close to the 
epithelial compartment in fibroepithelial lesions, and hypothesized that stromal growth in 
these tumours depended, in part, on the epithelial component. It was suggested that 
increasing malignancy correlated with loss of stromal dependency on the epithelium.95
Since then, there have been a number of studies supporting this view. Sawyer et al. 
demonstrated allelic imbalances in chromosomes 3p and 1q in both epithelial and stromal 
elements of phyllodes tumours.96 These authors also noted that stromal proliferation in 
benign phyllodes tumours was dependent on abnormalities in the Wnt pathway consequent 
to Wnt5a expression in the epithelial component, with malignant progression being linked to 
independence from the latter.91 E-cadherin is a known epithelial differentiation marker that 
is affected by the Wnt signalling pathway, and its expression in the epithelium of phyllodes 
tumours was correlated with recurrence and shorter tumour-specific survival.97 Feakins et al. 
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found epithelial platelet-derived growth factor (PDGF)/stromal PDGF receptor-β 
copositivity that correlated with disease-related death in 43% of phyllodes tumours.98 Clonal 
abnormalities have been detected in both epithelial and stromal components of phyllodes 
tumours in studies by Dietrich et al.99 and Kuijper et al.39 Additional work on biomarker 
expression in epithelial and stromal elements of phyllodes tumours lends further credence to 
their interactions.16,97,100–102 For example, the level of CXCR4, an epithelial–stromal 
interaction-related molecule, was found to be increased in the stromal component of higher-
grade phyllodes tumours.10
Hormone receptors
Table 4 summarizes findings from studies that have evaluated the expression of hormone 
receptors in phyllodes tumours,103–109 with one report documenting HER2/c-erbB2 
reactivity as well.106 ERα expression was confined to the epithelial compartment, without 
any stromal positivity, with one study demonstrating an inverse correlation with grade.106 
ERβ expression, on the other hand, has been observed in stromal cells of phyllodes 
tumours.108,109 The practical significance of these observations is unclear. Although the 
current data indicate a limited role for hormones in phyllodes tumours, the recently 
discovered MED12 mutations in these tumours may lead to a resurgence of interest, as the 
MED12 abnormality is linked to aberrantly activated oestrogen signalling.44,50
Surgical margins
The mainstay of phyllodes tumour management has traditionally consisted of surgical 
excision with wide tumour-free margins, generally defined by some authors as at least 10 
mm.31 However, more recent data suggest that not all phyllodes tumours require excision 
with such wide margins.32,110,111 In cases of large tumours, this may render breast 
conservation impracticable.112,113 Table 5 summarizes pertinent findings from studies that 
have addressed surgical margins in phyllodes tumours.23–25,28,32,110,111,114–120
Drawing a parallel from an opinion advanced by Wood regarding the issue of surgical 
margins in invasive breast cancer, there appears to be a dearth of data supporting a precise 
width of tumour-free tissue that is significantly associated with reduced tumour 
recurrence.121 Although an increasing amount of normal tissue confers greater confidence in 
the adequacy of excision (with ensuing diminishing cosmetic results), a single layer of cells 
between the tumour and the surgical plane constitutes, in theory, a clear margin.121 This 
does not take into account myriad factors that may undermine the accuracy of representation 
in any slide, including tumour irregularity, multifocality, ink seepage, sampling and technical 
sectioning issues, among others. Onkendi et al., in a study of 67 borderline and malignant 
phyllodes tumours from the Mayo Clinic, found that the extent of surgical excision had no 
impact on disease-free survival.110 An analysis of 164 cases by Jang et al. revealed no 
significant local control advantage conferred by wide (at least 10 mm) margins over 
narrower margins.32 Lin et al., in a single-institution series of 33 cases, found no relationship 
between width of surgical margin and disease recurrence.111
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Notwithstanding the above, many institutions elect to offer additional surgical treatment for 
close margins. Mangi et al., in a study of 40 cases from the Massachusetts General Hospital, 
found that post-excision recurrences were confined to cases with positive margins, or 
margins of <10 mm. Following re-excision with a 10-mm clearance, patients remained 
recurrence-free.117 Yom et al., in a recent Korean study of 285 cases, investigated the benefit 
of a second excision following initial ‘inadequate’ (<10 mm) clearance. Tumour size and 
mitotic activity were found to be independently prognostic of local recurrence, whereas 
margin status and surgical procedure were not. On the basis of these findings, the group 
proposed that wide margins, if necessary via re-excision, should be the goal in treating small 
(<50 mm) tumours with high mitotic activity (>10 mitoses/10 HPFs), as these tumours 
constituted a distinct group associated with a significant (55.6%) local recurrence rate.120
As convincing evidence for an appropriate margin width in surgically excised phyllodes 
tumours remains elusive, it may be pragmatic to consider tumour on ink, or <1 mm, as a 
positive margin. A conservative approach can be accorded to benign phyllodes tumours that 
have been initially enucleated without margins.27,74,75 Excision with negative margins 
should be achieved for recurrent and malignant phyllodes tumours.
Because of the infrequency of nodal disease in phyllodes tumours, most investigators do not 
recommend routine axillary dissection.29,115,117,122–124
Adjuvant therapy
Adjuvant radiation therapy has been offered to patients with malignant phyllodes tumours on 
an individualized basis, although its precise role is controversial.23,118,125–128 An analysis of 
3120 malignant cases from the US National Cancer Data Base by Gnerlich et al. showed a 
pronounced increase in the use of radiotherapy (9.5% in 1998–1999 versus 19.5% in 2008–
2009), which, although being associated with reduced local recurrence, had no impact on 
disease-free or overall survival.129 In a study of malignant phyllodes tumours by Mitus et al., 
conservatively treated cases were subjected to radiation if tumour-free margins were <10 
mm, whereas no adjuvant therapy was administered if margins were wide (≥10 mm). The 
two conservatively treated groups showed identical 5-year disease-free survival rates.119 
Belkacémi et al., in an analysis of cases collected from the Rare Cancer Network between 
1971 and 2003, found that adjuvant radiotherapy for borderline and malignant tumours 
yielded superior 10-year local control rates (86% with radiation versus 59% without 
radiation), but no survival benefit.29
There are no randomized clinical trials assessing the role of adjuvant chemotherapy in 
malignant phyllodes tumours. The merits of systemic therapy are therefore considered on a 
case-by-case basis.
Summary and practical recommendations
Phyllodes tumours present distinct challenges relating to their diagnosis, classification, 
predicted behaviour, and clinical management. On the basis of the currently available 
knowledge, a few practical recommendations may be useful:
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1. Grading of phyllodes tumours should aim to achieve accuracy and 
consistency at the benign and malignant ends of the spectrum.
2. Definitive distinction between cellular fibroadenomas and benign 
phyllodes tumours may not be crucial, in light of similar reported 
recurrence rates. The term benign fibroepithelial lesion/neoplasm may be 
recommended for cases where clear diagnostic distinction cannot be made, 
although this should be used sparingly.
3. Malignant phyllodes tumours are diagnosed when there are marked 
stromal hypercellularity, atypia, increased mitoses of ≥10/10 HPFs, 
permeative tumour borders, and stromal overgrowth. The presence of a 
malignant heterologous component places the tumour into the malignant 
category regardless of other histological features.
4. A conservative approach can be accorded to benign phyllodes tumours that 
have been initially enucleated without margins.
5. Excision with negative margins should be achieved for recurrent and 
malignant phyllodes tumours. Most would recommend that borderline 
tumours should also be completely excised. Although the literature often 
refers to a margin width of at least 10 mm, a robust evidence base to 
support this approach is lacking. Therefore, an ideal margin width remains 
to be determined, and may need to be considered in relation to factors such 
as tumour size and cosmesis.
6. From a diagnostic and management perspective, it is important to 
accurately recognize malignant phyllodes tumours, which should be 
surgically eradicated and effectively treated at diagnosis, as these tumours 
have a well-established but relatively infrequent risk of metastasis and 
death.
7. The role of adjuvant radiation therapy in borderline and malignant 
tumours remains to be defined. Routine axillary dissection is not 
recommended.
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Figure 1. 
Assessment of stromal cellularity in phyllodes tumours. (A) Mild hypercellularity with 
slightly increased cellularity, where stromal nuclei are non-overlapping. (B) Moderate 
hypercellularity with some overlapping stromal nuclei. (C) Marked hypercellularity with 
many overlapping stromal nuclei.
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Figure 2. 
Assessment of stromal atypia in phyllodes tumours. (A) Mild nuclear atypia shows minimal 
variation in nuclear size with even chromatin and smooth nuclear contours. (B) Moderate 
nuclear atypia with more variation in nuclear size and irregular nuclear membranes. (C) 
Marked nuclear atypia with marked nuclear pleomorphism, hyperchromasia, and irregular 
nuclear contours.
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Figure 3. 
Phyllodes tumour graded as borderline, as it did not fulfil all criteria of malignancy. (A) 
Rounded pushing contour of the tumour. (B) Stromal hypercellularity was of moderate 
degree, accompanied by focally marked nuclear atypia. (C) Higher magnification of atypical 
stromal cells showed hyperchromatic nuclei, prominent nucleoli, and occasional mitoses 
(arrow).
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Figure 4. 
Malignant phyllodes tumour with metastasis to the lung. (A) Low magnification of the 
primary breast phyllodes tumour with a cystic space into which stromal fronds projected. 
Part of the tumour showed a fibroadenoma-like appearance, whereas the remaining parts 
were more cellular. (B) Higher magnification of the cellular stromal areas showed sheets of 
plump spindled cells with enlarged vesicular nuclei with distinct nucleoli and scattered 
mitoses. Several osteoclastic giant cells were dispersed among the spindled cells. (C) 
Metastasis to the lung 1 year later showed a similar abnormal spindled population with 
scattered osteoclastic giant cells. No epithelial component was present in the metastasis.
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Figure 5. 
Cellular fibroepithelial neoplasm that raised the differential diagnosis of a cellular 
fibroadenoma versus a benign phyllodes tumour. (A) Low magnification showed a few 
elongated epithelium-lined clefts with stromal mounds. Mild stromal hypercellularity was 
observed. (B) Higher magnification of a stromal frond pushing into the clefted space that 
contained blood and haemosiderophages, with accentuation of stromal nuclei in the peri-
epithelial zone.
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Figure 6. 
Malignant phyllodes tumour with liposarcoma. (A) Stromal fronds contained cells with 
marked nuclear pleomorphism with a few bizarre cells. (B) Among the abnormal stromal 
cells were scattered lipoblasts featuring hyperchromatic scalloped nuclei with vacuolated 
cytoplasm, indicating a liposarcomatous component.
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Table 1
Metastatic rates in phyllodes tumours according to grade
Authors (case number), publication year
Tumour grade, % (no.)
Benign Borderline Malignant
Chaney et al.23 (n = 101), 2000 1.7 (1/59) 0 (0/12) 26.7 (8/30)
Chen et al.24 (n = 172), 2005 0 (0/131) 0 (0/12) 10.3 (3/29)
Sotheran et al.25 (n = 50), 2005 0 (0/29) 0 (0/12) 11.1 (1/9)
Abdalla et al.26 (n = 79), 2006 3.2 (1/31) 11.1 (3/27) 28.6 (6/21)
Tan et al.27 (n = 37), 2006 0 (0/22) 0 (0/9) 50 (3/6)
Cheng et al.28 (n = 182), 2006 0 (0/138) 7.7 (1/13) 9.7 (3/31)
Belkacémi et al.29 (n = 443), 2008 0 (0/284) 2.5 (2/80) 16.5 (13/79)
Lenhard et al.30 (n = 33), 2008 0 (0/13) 0 (0/9) 27.3 (3/11)
Guillot et al.31 (n = 165), 2010 0 (0/114) 0 (0/37) 14.3 (2/14)
Tan et al.4 (n = 605), 2012 0 (0/440) 0 (0/111) 13 (7/54)
Jang et al.32 (n = 164), 2012 0 (0/82) 0 (0/42) 10 (4/40)
Sawalhi et al.33 (n = 42), 2013 0 (0/16) 0 (0/9) 35.3 (6/17)
Wang et al.34 (n = 227), 2014 0 (0/125) 1.8 (1/55) 10.6 (5/47)
Bumpers et al.35 (n = 50), 2015 0 (0/40) 0 (0/3) 28.5 (2/7)
Total 0.13 (2/1524) 1.62 (7/431) 16.71 (66/395)
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Table 2
Summary of studies evaluating the relationship between fibroadenomas and phyllodes tumours
Study, year Summary of findings
Noguchi et al.,36 1993 Epithelial and stromal cells were polyclonal in all of 10 fibroadenomas, whereas stromal cells were monoclonal in 
all of five phyllodes tumours
Noguchi et al.,37 1995 The same allele of the androgen receptor gene was inactivated in fibroadenomas and phyllodes tumours in each of 
three patients with both tumours
Kasami et al.,38 1998 5% (1/20) of ‘complex’ fibroadenomas and 1% (1/25) of ‘simple’ fibroadenomas showed stromal monoclonality. 
The one ‘simple’ fibroadenoma coexisted with a phyllodes tumour component, which showed similar stromal 
monoclonality
Kuijper et al.,39 2002 Areas of ‘stromal expansion’ in three of 25 fibroadenomas were monoclonal. In addition, nine of 12 phyllodes 
tumours showed stromal monoclonality
Wang et al.,40 2006 Phyllodes tumours harboured a subset of LOH loci, which were absent in fibroadenomas. Primary and recurrent 
phyllodes tumours shared common regions of LOH
Hodges et al.,41 2009 A single, laser-microdissected fibroadenoma and phyllodes tumour (synchronous) showed similar allelic loss 
(D7S522) in both components, wheras the phyllodes component showed additional losses at TP53 and D22S264
Abe et al.,42 2011 Eleven of 36 cases of malignant phyllodes tumours were associated with prior diagnoses of fibroadenomas
Foucar et al.,43 2012 A recent report of benign phyllodes tumours that developed in a mother and daughter pair raised the possibility of a 
genetic predisposition for phyllodes tumour development
Lim et al.,44 2014 Recurrent somatic mutations in exon 2 of MED12 were discovered in 59% of 98 fibroadenomas on exome 
sequencing, with 71% of mutations occurring in codon 44
Cani et al.,45 2015 MED12 mutations were found in phyllodes tumours of all histological grades on next-generation sequencing. 
Additional mutations in p53, RB1 and NF1, as well as high-level copy number alterations, such as amplifications in 
EGFR and IGF1R, were features of malignant tumours
Yoshida et al.,46 2015 All grades of phyllodes tumours showed MED12 mutations. Microdissection analysis confirmed MED12 mutations 
to be stroma-confined in fibroadenomas and phyllodes tumours
Piscuoglio et al.,47 2015 Malignant phyllodes tumours were significantly less likely to harbour MED12 mutations than fibroadenomas, and 
benign and borderline phyllodes tumours
Nagasawa et al.,48 2015 MED12 mutations were found in 67% of fibroadenomas (6/9) and in 45% of phyllodes tumours (5/11)
Pfarr et al.,49 2015 60% of all fibroepithelial breast lesions (fibroadenomas and phyllodes tumours) showed MED12 mutations. 
Intracanalicular fibroadenomas showed the highest frequency of mutations (82%), whereas malignant phyllodes 
tumours were least likely to contain the mutations (20%)
Ng et al.,50 2015 62.5% (70/112) of phyllodes tumours showed MED12 mutations. Tumours with MED12 mutations were associated 
with longer disease-free survival, whereas absence of MED12 mutations was correlated with a higher likelihood of 
recurrence
LOH, loss of heterozygosity.
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Table 3
Distinguishing histological features of malignant spindle cell breast lesions
Tumour Malignant phyllodes tumour
Spindle cell metaplastic 
breast carcinoma Breast sarcoma
Epithelial component Benign; distinct leaf-like pattern Malignant Absent
Ductal carcinoma in situ Usually absent May be present Usually absent
Squamous differentiation Usually absent May be present Absent
Heterologous differentiation May be present May be present Tumour-specific differentiation
Broad-spectrum cytokeratins Usually negative (−/+) in spindle cells Invariably positive (+/−) in 
spindle cells
Usually negative (−/+) in spindle cells
p63 Usually negative (−/+) in spindle cells Usually positive (+/−) in 
spindle cells
Usually negative (−/+) in spindle cells
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Table 4
Summary of studies evaluating hormone receptor expression in phyllodes tumours
Study, year Summary of findings
Rao et al.,103 1981 With the dextran charcoal method, tissue samples from five phyllodes tumours and 13 fibroadenomas were analysed 
for hormone receptors. PR was expressed in five of five phyllodes tumours and in 11 of 13 fibroadenomas. ER was 
expressed in one of five phyllodes tumours and in two of 13 fibroadenomas. The volumes occupied by epithelium 
and stroma in each tumour were in keeping with stromal expression of PR and epithelial expression of ER
Mechtersheimer et 
al.,104 1990
Three phyllodes tumours and 13 fibroadenomas studied showed PR and ER expression confined to ductal epithelial 
cells
Singh et al.,105 1996 Sixteen phyllodes tumours (nine benign; seven malignant) studied showed PR expression in all cases (16/16) and ER 
expression in most cases (12/16). Hormone receptor expression was limited to luminal epithelial nuclei
Shpitz et al.,106 2002 Twenty-three phyllodes tumour studied showed epithelial c-erb-B2 (HER2) reactivity in 61% of cases; however, no 
correlation with histological features was found
Tse et al.,107 2002 One hundred and forty-three phyllodes tumours studied showed an inverse relationship between epithelial hormonal 
(ER and PR) expression and tumour grade. Hormonal expression was largely confined to the epithelial component, 
with ER positivity in 58% of the epithelium and 2.8% of stromal cells, and PR positivity in 74.8% of the epithelium 
and 1.4% of stromal cells. In the same study, AR expression in both the stromal and epithelial components of 
phyllodes tumours was low (<5%) across all three tumour grades. Epithelial ER expression showed correlation with 
stromal mitotic activity, and was predictive of tumour grade
Sapino et al.,108 2006 Thirty-three fibroadenomas and 40 phyllodes tumours studied showed ERα expression confined to epithelial cells, 
whereas this was undetectable in tumour stroma. Conversely, ERβ was expressed by both epithelial and stromal 
components of these tumours, which may be related to differentiation of stromal fibroblasts towards a 
myofibroblastic phenotype, as implied by correlation of ERβ positivity with stromal smooth muscle actin and 
calponin expression
Kim et al.,109 2012 Eighty-two phyllodes tumours studied showed stromal ERβ expression in 24 (29.3%) cases, whereas ERα and PR 
were expressed only in the epithelial component. Stromal Ki67 expression correlated with epithelial ERβ, epithelial 
AR and stromal ERβ expression. However, no significant association was found between hormonal receptor 
expression and phyllodes tumour grade
AR, androgen receptor; ER, oestrogen receptor; PR, progesterone receptor.
Note: apart from the first study, the remaining referenced studies utilized immunohistochemical analysis.
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Table 5
Surgical margins in phyllodes tumours
Study, year Pertinent findings
Definition of a 
wide margin
Ciatto et al.,114 1992 A multicentre study of 59 cases found enucleation and wide excision to be associated with a 
greater incidence of local recurrence (three of five cases and 12 of 30 cases respectively) than 
mastectomy (two of 24 cases)
Not specified
Reinfuss et al.,115 1996 A study of 170 cases showed wide local excision to achieve 5-year disease-free survival rates of 
98.7%, 80% and 75% for patients with benign, borderline and malignant tumours, respectively
10–20 mm
Barth,116 1999 A MEDLINE review of 944 cases showed differences in local recurrence rates of benign, 
borderline and malignant tumours to be 21% (111/540), 46% (18/39) and 65% (26/40) after local 
excision, and 8% (17/212), 29% (20/68) and 36% (16/45) after wide excision, respectively
10–20 mm
Mangi et al.,117 1999 A study of 40 cases showed post-excision recurrence to be confined to cases with positive 
margins, or margins <10 mm
10 mm
Chaney et al.,23 2000 A study of 101 patients showed low recurrence rates (actuarial 10-year local failure rates of 7% 
for benign and borderline tumours, and 9% for malignant tumours, respectively) when local 
excision with appropriate surgical margins was used as primary treatment of phyllodes tumours, 
provided that the tumour-to-breast ratio was amenable to good cosmesis
≥10 mm
Chen et al.,24 2005 A study of 172 cases showed local excision to be associated with a high percentage (18.3%) of 
positive margins
>10 mm
Sotheran et al.,25 2005 A retrospective analysis of 50 phyllodes tumours found breast conservation surgery to be as 
successful as mastectomy, provided that margins were sufficiently wide
>1 mm
Macdonald et al.,118 
2006
A SEER review of 821 malignant phyllodes tumours from 1983 to 2002 found no benefit 
conferred by mastectomy over wide excision with regard to disease-specific mortality
Not specified
Cheng et al.,28 2006 A study of 182 phyllodes tumours showed positive surgical margins to be the only independent 
predictor of recurrence. Tumour grade progression was found in 16% of recurrent cases
10–20 mm
Jang et al.,32 2012 A study of 164 cases revealed no significant local control advantage conferred by wide margins 
over narrower margins, provided that the narrower margins were tumour-negative
10 mm
Lin et al.,111 2013 A study of 33 cases showed no relationship between width of surgical margin and disease 
recurrence
>10 mm
Mitus et al.,119 2014 A study of 70 cases showed no significant difference in 5-year disease-free survival between 
patients treated with mastectomy (n = 34, 82.4%) and those treated with breast conservation 
surgery with clear microscopic margins (n = 36, 83.3%)
≥10 mm
Onkendi et al.,110 2014 A study of 67 cases of borderline and malignant phyllodes tumours showed the extent of surgical 
excision to have no impact on disease-free survival
≥10 mm
Yom et al.,120 2015 A study of 285 cases investigated the benefit of a second excision following initial inadequate 
(<10 mm) clearance. Tumour size and mitotic activity were found to be independently prognostic 
of local recurrence, whereas margin status and surgical procedure were not. It was proposed that 
wide margins, if necessary via re-excision, should be the goal in treating small (<50 mm) 
tumours with high mitotic activity (>10 mitoses per 10 high-power fields), as these tumours 
constituted a distinct group associated with a significant (55.6%) local recurrence rate
10 mm
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